ChiCTR2000036618: Precision therapy strategy for osteosarcoma based on molecular typing: a prospective, single-center, one-brachial umbrella phase II exploratory clinical study |
|
|
| Not yet recruiting | N/A | 18 | | Everolimus 5mg qd + Anlotinib 8mg-12mg day 1-21，28-day cycle ;Camrelizumab 3mg/kg + Ipilimumab 1 mg/kg, 21-days cycle ;Palbociclib 125mg day 1-21 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Olaparib 300mg bid day 1-14 + gemcitabine 600mg/m2 day 1,8,15,22, 28-days cycle ;Metformin 2000mg qd + gemcitabine 675mg/m2 day 1,8, docetaxol 900mg/m2 day 8， 21-days cycle | Shanghai General Hospital; Shanghai General Hospital, Project special fund | osteosarcoma | | | | |
